Inspira Technologies Oxy B.H.N. Ltd. (IINN) has released an update.
Inspira Technologies Oxy B.H.N. Ltd., in collaboration with Ennocure MedTech Ltd., has reported a breakthrough in preventing bloodstream infections with their bio-electronic treatment, showing a 100% reduction in bacterial growth within 24 hours during in vitro studies. This technology, intended for patients in intensive care, is set to be integrated into Inspira’s ART patient treatment system. The next step involves ex vivo model testing ahead of prospective in-human trials, marking a significant advancement in infection prevention and patient care.
For further insights into IINN stock, check out TipRanks’ Stock Analysis page.
